The baseline HbA1c in the tirzepatide arms was 8.26%8.32% and 8.25% in the study arm receiving a placebo
Zepbound's standard maintenance doses range from 5 mg to 15 mg weekly, adjusted based on treatment outcomes and tolerability (Zepbound, FDA, 2025)
Zepbound is the only dual-action GLP-1/GIP medication approved for weight management, with the highest average weight loss in clinical trials (22%)
In clinical trials: Semaglutide: Approximately 7% discontinued due to adverse events Tirzepatide: Approximately 4-7% discontinued due to adverse events (dose dependent) Retatrutide: Approximately 6-10% discontinued due to adverse events (dose dependent) These rates are relatively close, suggesting that despite the differences in mechanism and side effect profiles, all three medications are tolerable for the vast majority of people who start them
The molecular weight is 4813.53 Da and the empirical formula is C 225 H 348 N 48 O 68
After booking a consultation, you will meet your healthcare provider online via a secure video call
